If you listen to the Webconference posted on Scancell's website he also says about Moditope - "We're getting already significant interest from pharmaceutical companies, even at this early stage and with this particular platform we think its realistic to expect to do some licensing deals in the short to medium term."
Then there is the Sunday Times article where the CEO says the following about what he expects to follow with SCIB1 after publishing encouraging data last month - “We are looking at 2014 as the year we consummate a relationship or a deal to take this forward.”
(borrowed from LSE)
I don't think we'll have to wait long for those things to materialize. As soon as we get a licencing deal the share price will undoubtedly reflect that. Note that with Moditope patent application published, Scancell can now do licencing deals on both platforms (Immunobody and on Moditope).
It's also interesting to note that Inovio had a similar mcap before their deal with Roche, and has grown 800% since. You have a rare opportunity here to buy into a similar company before a deal is struck, which is pretty much guaranteed to happen BTW. And if you look at Scancell's results you'll see that they are significantly better than those of Inovio.
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM